Appointment of Director of Business Development

RNS Number : 8878F

OptiBiotix Health PLC

02 August 2016

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Appointment of Director of Business Development

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the appointment of Luis Gosalbez as Director of Business Development, effective immediately. Luis will join the senior management team and whilst this is not the main board (PLC), Luis may take on a board position within OptiBiotix's divisional structure as these develop into separate legal entities, as announced in OptiBiotix's strategy update on 5 July 2016. 

Luis brings a strong scientific background, an understanding of the microbiome and expertise in consumer healthcare, probiotics and the development of novel Live Biotherapeutic Products.  Luis's scientific research interests include publications and presentations on the 'Use of probiotics and prebiotics in the management of obesity', 'Food and Pharma - coming closer together' and 'Key regulatory issues for the development of pharmabiotics in Europe'.

Luis is multilingual having worked at various times in Germany, Spain, and South Korea as a researcher, analyst, and as a director of strategic projects exploring opportunities in consumer healthcare, the microbiome, and biotherapeutics.  His experience of the Asian market will help enhance our understanding and capability to support wider internationalisation of products and create new joint development opportunities. He has a degree in biology from the Universidad Complutense de Madrid in Spain and an MPhil. from the University of Cambridge.

Stephen O'Hara, CEO of OptiBiotix, commented: "Luis's scientific and commercial experience in the microbiome space across food, biotech, and pharma provides additional breadth and capability to help capitalise on the growing number of microbiome opportunities.  His multilingual skills and experience in working in overseas markets, particularly Asia, will help enhance our access to these markets and support commercialisation of our pipeline of opportunities.  Luis's skills in managing multiple projects brings additional capacity to manage the increasing number of product development agreements currently in place with international partners, in addition to those anticipated in the future." 

For further information, please contact:

OptiBiotix Health plc	www.optibiotix.com
Stephen O'Hara, Chief Executive	Contact via Walbrook below
Cairn Financial Advisers LLP	Tel: [phone]
Liam Murray
Hybridan LLP (Joint Broker) Claire Louise Noyce	Tel: [phone]
Peterhouse Corporate Finance Ltd (Joint Broker)	Tel: [phone]
Lucy Williams / Duncan Vasey
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

END

 

 

MSCLLFVETEILIIR